Therapeutic potentials of pentoxifylline for treatment of cardiovascular diseases

Experimental and Clinical Cardiology

Volumn 9, Issue 2, 2004, Pages 103-111

  Zhang, Ming ^b   Xu, Yan Jun ^b   Mengi, Shushma A ^b   Arneja, Amarjit S ^a   Dhalla, Naranjan S ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL RESEARCH CENTRE   (Canada)

Author keywords

Blood viscosity; Ischemia reperfusion injury; Pentoxifylline; Peripheral vascular disease; Platelet function

Indexed keywords

A 802715; ADENOSINE A1 RECEPTOR; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENYLATE CYCLASE; ALBIFYLLINE; AMINOPHYLLINE; CAFFEINE; CYCLIC AMP; DRUG METABOLITE; GLYCEROL NITRATE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; LISOFYLLINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; METHYLXANTHINE DERIVATIVE; PENTOXIFYLLINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHOLIPASE D; PROSTACYCLIN; PROSTAGLANDIN G; THEOBROMINE; THEOPHYLLINE; TORBAFYLLINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; XANTHINE DERIVATIVE;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BLOOD RHEOLOGY; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CYTOKINE PRODUCTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; ENZYME INHIBITION; ERYTHROCYTE DEFORMABILITY; FIBRINOLYSIS; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEMODYNAMIC PARAMETERS; HUMAN; LEUKOCYTE ADHERENCE; LIVER CIRRHOSIS; LIVER FIBROSIS; MACROPHAGE MIGRATION INHIBITION; MUSCLE ISCHEMIA; NONHUMAN; PATHOGENESIS; PERIPHERAL VASCULAR DISEASE; PULMONARY HYPERTENSION; RAT; REVIEW; SIDE EFFECT; SMOOTH MUSCLE RELAXATION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION;

EID: 4444353679     PISSN: 12056626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (144)

1. Rall TW. Drug used in the treatment of asthma. In: Limbird LE, Milinoff PB, Ruddon RW, Gilman AG, Hardman JG, eds. The Pharmacological Basis of Therapeutics. New York: Pergramon Press, 1990:618-38.
2. Wesley GC, Brater DC, Jonson AR. Central nervous system stimulants. In: Kist K, ed. Goth's Medical Pharmacology. St Louis: Mosby Year Book, 1992:300-7.
3. Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy. Drugs 1987;34:50-97.
4. Eun BL, Liu XH, Barks JD. Pentoxifylline attenuates hypoxicischemic brain injury in immature rats. Pediatr Res 2000;47:73-8.
5. Muller R. Hemorheology and peripheral vascular diseases: A new therapeutic approach. J Med 1981;12:209-35.
6. Betticher DC, Keller H, Maly FE, Reinhart WH. The effect of endotoxin and tumour necrosis factor on erythrocyte and leucocyte deformability in vitro. Br J Haematol 1993;83:130-7.
7. Fossat C, Fabre D, Alimi Y, et al. Leukocyte activation study during occlusive arterial disease of the lower limb: Effect of pentoxifylline infusion. J Cardiovasc Pharmacol 1995;25(Suppl 2):S96-100.
8. Klinzing S, Lesser T, Schubert H, Bartel M, Klein U. May pentoxifylline improve lung function after one-lung flooding? Res Exp Med (Berl) 2001;200:69-76.
9. Salyer JL, Bohnsack JF, Knape WA, Shigeoka AO, Ashwood ER, Hill HR. Mechanisms of tumor necrosis factor-alpha alteration of PMN adhesion and migration. Am J Pathol 1990;136:831-41.
10. Samlaska CP, James WD. Superficial thrombophlebitis. I. Primary hypercoagulable states. J Am Acad Dermatol 1990;22:975-89.
11. Samlaska CP, Winfield EA. Pentoxifylline. J Am Acad Dermatol 1994;30:603-21.
12. Schmalzer EA, Chien S. Filterability of subpopulations of leukocytes: Effect of pentoxifylline. Blood 1984;64:542-6.
13. Weiss DJ, Evanson OA. Evaluation of lipopolysaccharide-induced activation of equine neutrophils. Am J Vet Res 2002;63:811-5.
14. Dhote-Burger P, Vuilleminot A, Lecompte T, et al. Neutrophil degranulation related to the reperfusion of ischemic human heart during cardiopulmonary bypass. J Cardiovasc Pharmacol 1995;25(Suppl 2):S124-9.
15. Horton JW, White DJ. Free radical scavengers prevent intestinal ischemia-reperfusion-mediated intestinal dysfunction. J Surg Res 1993;55:282-9.
16. Myers SI, Horton JW, Hernandez R, Walker PB, Vaughan WG. Pentoxifylline protects splanchnic prostacyclin synthesis during mesenteric ischemia/reperfusion. Prostaglandins 1994;47:137-50.
17. Schermuly RT, Roehl A, Weissmann N, et al. Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001;281:L1361-8.
18. Manrique RV, Manrique V. Platelet resistance to prostacyclin. Enhancement of the antiaggregatory effect of prostacyclin by pentoxifylline. Angiology 1987;38:101-8.
19. Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun 1988;155:1230-6.
20. Adams JG Jr, Dhar A, Shukla SD, Silver D. Effect of pentoxifylline on tissue injury and platelet-activating factor production during ischemia-reperfusion injury. J Vasc Surg 1995;21:742-8.
21. White PJ, Nguyen TT. Chronic caffeine treatment causes changes in cardiac adenosine receptor function in rats. Pharmacology 2002;65:129-35.
22. Sardao VA, Oliveira PJ, Moreno AJ. Caffeine enhances the calcium-dependent cardiac mitochondrial permeability transition: Relevance for caffeine toxicity. Toxicol Appl Pharmacol 2002;179:50-6.
23. Vlachopoulos C, Hirata K, Stefanadis C, Toutouzas P, O'Rourke MF. Caffeine increases aortic stiffness in hypertensive patients. Am J Hypertens 2003;16:63-6.
24. Okafor CC, Saunders L, Li X, et al. Myofibrillar responsiveness to cAMP, PKA, and caffeine in an animal model of heart failure. Biochem Biophys Res Commun 2003;300:592-9.
25. Mitrouska I, Kondili E, Prinianakis G, Siafakas N, Georgopoulos D. Effects of theophylline on ventilatory poststimulus potentiation in patients with brain damage. Am J Respir Crit Care Med 2003;167:1124-30.
26. Cawley MJ, Al-Jazairi AS, Stone EA. Intravenous theophylline - an alternative to temporary pacing in the management of bradycardia secondary to AV nodal block. Ann Pharmacother 2001;35:303-7.
27. Dixon WC, Bauch TD. Effects of theophylline on exercise indices in a patient with chronotropic incompetence. Clin Cardiol 2000;23:787-9.
28. Fang S, Sherwood RA, Gamsu HR, Marsden JT, Peters TJ, Greenough A. Comparison of the effects of theophylline and caffeine on serum erythropoietin concentration in premature infants. Eur J Pediatr 1998;157:406-9.
29. Trivedi H, Lal SM. A prospective, randomized, open labeled crossover trial of fosinopril and theophylline in post renal transplant erythrocytosis. Ren Fail 2003;25:77-86.
30. Yesildag O, Yazici M, Yilmaz O, Ucar R, Sagkan O. The effect of aminophylline infusion on the exercise capacity in patients with syndrome X. Acta Cardiol 1999;54:335-7.
31. Altun A, Kirdar C, Ozbay G. Effect of aminophylline in patients with atropine-resistant late advanced atrioventricular block during acute inferior myocardial infarction. Clin Cardiol 1998;21:759-62.
32. Marzi I, Maier M, Herzog C, Bauer M. Influence of pentoxifylline and albifylline on liver microcirculation and leukocyte adhesion after hemorrhagic shock in the rat. J Trauma 1996;40:90-6.
33. Hoffmann H, Weis M, Frank G, Birg A, Schonharting MM, Jochum M. Amelioration of endotoxin-induced acute lung injury in pigs by HWA 138 and A 80 2715: New analogs of pentoxifylline. Shock 1995;4:166-70.
34. Berens KL, Langston JD, Wasan KM, Luke DR. Influence of pentoxifylline and related analogues in endotoxemic renal failure. Circ Shock 1991;34:344-8.
35. Schade UF. The role of prostacyclin in the protective effects of pentoxifylline and other xanthine derivatives in endotoxin action in mice. Eicosanoids 1989;2:183-8.
36. Niehorster M, Schonharting M, Wendel A. A novel xanthine derivative counteracting in vivo tumor necrosis factor alpha toxicity in mice. Circ Shock 1992;37:270-3.
37. Lin Y, Goebels J, Rutgeerts O, et al. Use of the methylxanthine derivative A802715 in transplantation immunology: I. Strong in vitro inhibitory effects on CD28-costimulated T cell activities. Transplantation 1997;63:1813-8.
38. Lin Y, Segers C, Mikhalsky D, Tjandra-Maga TB, Schonharting M, Waer M. Use of the methylxanthine derivative A802715 in transplantation immunology: II. In vivo experiments. Transplantation 1997;63:1734-8.
39. Ambrus JL, Stadler S, Kulaylat M. Hemorrheologic effects of metabolites of pentoxifylline (Trental). J Med 1995;26:65-75.
40. Miller K, Louie A, Baltch AL, Smith RP, Davis PJ, Gordon MA. Pharmacokinetics of pentoxifylline and its metabolites in healthy mice and in mice infected with Candida albicans. Antimicrob Agents Chemother 1998;42:2405-9.
41. Honess DJ, Dennis IF, Bleehen NM. Pentoxifylline: Its pharmacokinetics and ability to improve tumour perfusion and radiosensitivity in mice. Radiother Oncol 1993;28:208-18.
42. Lillibridge JA, Kalhorn TF, Slattery JT. Metabolism of lisofylline and pentoxifylline in human liver microsomes and cytosol. Drug Metab Dispos 1996;24:1174-9.
43. Clarke E, Rice GC, Weeks RS, et al. Lisofylline inhibits transforming growth factor beta release and enhances trilineage hematopoietic recovery after 5-fluorouracil treatment in mice. Cancer Res 1996;56:105-12.
44. Hasegawa N, Oka Y, Nakayama M, et al. The effects of post-treatment with lisofylline, a phosphatidic acid generation inhibitor, on sepsis-induced acute lung injury in pigs. Am J Respir Crit Care Med 1997;155:928-36.
45. Bursten SL. Interaction of lipopolysaccharide with a mammalian lyso-phosphatidate acyltransferase (LPAAT) transfected into E. coli, and effect of lisofylline on LPAAT transfected into mammalian cells. Prog Clin Biol Res 1998;397:345-56.
46. Rogers SJ, Sherman DG. Pathophysiology and treatment of acute ischemic stroke. Clin Pharm 1993;12:359-76.
47. Kowal P. Hemorheology in cerebral ischemia. Neurol Neurochir Pol 1996;30(Suppl 2):7-11.
48. Meyer JS. Regulation of cerebral hemodynamics in health and disease. Eur Neurol 1983;22(Suppl 1):47-60.
49. Meyer JS, Okayasu H, Tachibana H, Okabe T. Stable xenon CT CBF measurements in prevalent cerebrovascular disorders (stroke). Stroke 1984;15:80-90.
50. Sipos C, Popoviciu L, Motoc R, Marian R. Relationships between the degree and topography of the atherosclerotic lesions of the extracranial carotid axis with the clinical form of ischaemic attack, evaluated by duplex methodology. Rom J Neurol Psychiatry 1990;28:157-62.
51. Dormandy JA. Red cell deformability. Eur Neurol 1983;22(Suppl 1):23-9.
52. De Clerck F, David JL. Pharmacological control of platelet and red blood cell function in the microcirculation. J Cardiovasc Pharmacol 1981;3:1388-412.
53. Bolton LM, Thomas TH, Dunlop W. Erythrocyte ion and water balance and membrane potential in the puerperium of normal pregnancy. Br J Obstet Gynaecol 1996;103:547-51.
54. Cabantchik ZI. Erythrocyte membrane transport. Novartis Found Symp 1999;226:6-16.
55. Weng X, Cloutier G, Beaulieu R, Roederer GO. Influence of acute-phase proteins on erythrocyte aggregation. Am J Physiol 1996;271:H2346-52.
56. Marcel GA, George C. Pentoxifylline and cerebrovascular diseases. Eur Neurol 1983;22(Suppl 1):89-97.
57. Frampton JE, Brogden RN. Pentoxifylline (oxpentifylline). A review of its therapeutic efficacy in the management of peripheral vascular and cerebrovascular disorders. Drugs Aging 1995;7:480-503.
58. Schubotz R, Muhlfellner O. The effect of pentoxifylline on erythrocyte deformability and on phosphatide fatty acid distribution in the erythrocyte membrane. Curr Med Res Opin 1977;4:609-17.
59. Bowton DL, Stump DA, Prough DS, Toole JF, Lefkowitz DS, Coker L. Pentoxifylline increases cerebral blood flow in patients with cerebrovascular disease. Stroke 1989;20:1662-6.
60. Ganser V, Boksay I. Effect of pentoxifylline on cerebral edema in cats. Neurology 1974;24:487-93.
61. Muller R, Schroer R. Cerebrovascular circulatory disorders: New aspects of pathophysiology and therapy. J Med 1979;10:347-64.
62. Ytrehus K. The ischemic heart - experimental models. Pharmacol Res 2000;42:193-203.
63. Canadian Task Force for Cardiovascular Science. A Joint Initiative of the Heart and Stroke Foundation of Canada and the Canadian Cardiovascular Society. Can J Cardiol 1993;9:699-735.
64. Cain BS, Meldrum DR, Dinarello CA, Meng X, Banerjee A, Harken AH. Adenosine reduces cardiac TNF-alpha production and human myocardial injury following ischemia-reperfusion. J Surg Res 1998;76:117-23.
65. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992;257:387-9.
66. Meldrum DR, Dinarello CA, Shames BD, et al. Ischemic preconditioning decreases postischemic myocardial tumor necrosis factor-alpha production. Potential ultimate effector mechanism of preconditioning. Circulation 1998;98:II214-8.
67. Mathias S, Dressler KA, Kolesnick RN. Characterization of a ceramide-activated protein kinase: Stimulation by tumor necrosis factor alpha. Proc Natl Acad Sci USA 1991;88:10009-13.
68. Goldhaber JI, Kim KH, Natterson PD, Lawrence T, Yang P, Weiss JN. Effects of TNF-alpha on [Ca2+]i and contractility in isolated adult rabbit ventricular myocytes. Am J Physiol 1996;271:H1449-55.
69. Bergman MR, Holycross BJ. Pharmacological modulation of myocardial tumor necrosis factor alpha production by phosphodiesterase inhibitors. J Pharmacol Exp Ther 1996;279:247-54.
70. Krown KA, Page MT, Nguyen C, et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996;98:2854-65.
71. Vandenabeele P, Declercq W, Vanhaesebroeck B, Grooten J, Fiers W. Both TNF receptors are required for TNF-mediated induction of apoptosis in PC60 cells. J Immunol 1995;154:2904-13.
72. Barnett JC, Touchon RC. Therapy of ischemic cardiomyopathy with pentoxifylline. Angiology 1990;41:1048-52.
73. Dauber IM, Lesnefsky EJ, Ashmore RC, et al. Coronary vascular injury due to ischemia-reperfusion is reduced by pentoxifylline. J Pharmacol Exp Ther 1992;260:1250-6.
74. Gale SC, Hokama JY, Ritter LS, Gorman GD, Copeland JG, McDonagh PF. Pentoxifylline reduces coronary leukocyte accumulation early in reperfusion after cold ischemia. Ann Thorac Surg 2001;71:1305-11.
75. Insel J, Halle AA, Mirvis DM. Efficacy of pentoxifylline in patients with stable angina pectoris. Angiology 1988;39:514-9.
76. Lechleitner P, Genser N, Mair J, et al. Pentoxifylline influences acute-phase response in acute myocardial infarction. Clin Investig 1992;70:755.
77. Ulus AT, Aksoyek A, Katircioglu SF, Gokce P, Koc B. Preservation of myocardial functions by pentoxyphylline cardioplegia during and after cardiopulmonary bypass. Panminerva Med 2000;42:253-6.
78. Abraham E, Bursten S, Shenkar R, et al. Phosphatidic acid signaling mediates lung cytokine expression and lung inflammatory injury after hemorrhage in mice. J Exp Med 1995;181:569-75.
79. Semmler J, Gebert U, Eisenhut T, et al. Xanthine derivatives: Comparison between suppression of tumour necrosis factor-alpha production and inhibition of cAMP phosphodiesterase activity. Immunology 1993;78:520-5.
80. Molnar-Kimber K, Yonno L, Heaslip R, Weichman B. Modulation of TNF alpha and IL-1 beta from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Actions 1993;39:C77-9.
81. Bessler H, Gilgal R, Djaldetti M, Zahavi I. Effect of pentoxifylline on the phagocytic activity, cAMP levels, and superoxide anion production by monocytes and polymorphonuclear cells. J Leukoc Biol 1986;40:747-54.
82. Hou X, Baudry N, Lenoble M, Vicaut E. Leukocyte adherence in an ischemic muscle perfused by a collateral circulation. J Cardiovasc Pharmacol 1995;25(Suppl 2):S119-23.
83. Semmler J, Wachtel H, Endres S. The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-alpha production by human mononuclear cells. Int J Immunopharmacol 1993;15:409-13.
84. Sener G, Akgun U, Satiroglu H, Topaloglu U, Keyer-Uysal M. The effect of pentoxifylline on intestinal ischemia/reperfusion injury. Fundam Clin Pharmacol 2001;15:19-22.
85. Zhang M, Sethi R, Xu YJ, Dhalla NS. Increased production of TNF-alpha in hearts subjected to Ca2+-Paradox. J Mol Cell Cardiol 2003;35:A30. (Abst)
86. Zhang M, Xu YJ, Rathi SS, Dhalla NS. Effect of pentoxifylline on ischemia reperfusion-induced heart injury in rats. J Mol Cell Cardiol 2002;34:A24. (Abst)
87. Kishi M, Tanaka H, Seiyama A, et al. Pentoxifylline attenuates reperfusion injury in skeletal muscle after partial ischemia. Am J Physiol 1998;274:H1435-42.
88. Bottiger BW, Motsch J, Braun V, Martin E, Kirschfink M. Marked activation of complement and leukocytes and an increase in the concentrations of soluble endothelial adhesion molecules during cardiopulmonary resuscitation and early reperfusion after cardiac arrest in humans. Crit Care Med 2002;30:2473-80.
89. Gute DC, Ishida T, Yarimizu K, Korthuis RJ. Inflammatory responses to ischemia and reperfusion in skeletal muscle. Mol Cell Biochem 1998;179:169-87.
90. Kyriakides C, Austen W, Wang Y, et al. Skeletal muscle reperfusion injury is mediated by neutrophils and the complement membrane attack complex. Am J Physiol 1999;277:C1263-8.
91. Silver D, Dhar A, Slocum M, Adams JG, Shukla S. Rote of platelet-activating factor in skeletal muscle ischemia-reperfusion injury. Adv Exp Med Biol 1996;416:217-21.
92. Currie MS, Rao KM, Padmanabhan J, Jones A, Crawford J, Cohen HJ. Stimulus-specific effects of pentoxifylline on neutrophil CR3 expression, degranulation, and superoxide production. J Leukoc Biol 1990;47:244-50.
93. McCarty MF. Nitric oxide deficiency, leukocyte activation, and resultant ischemia are crucial to the pathogenesis of diabetic retinopathy/neuropathy - preventive potential of antioxidants, essential fatty acids, chromium, ginkgolides, and pentoxifylline. Med Hypotheses 1998;50:435-49.
94. Lorant DE, Patel KD, McIntyre TM, McEver RP, Prescott SM, Zimmerman GA. Coexpression of GMP-140 and PAF by endothelium stimulated by histamine or thrombin: A juxtacrine system for adhesion and activation of neutrophils. J Cell Biol 1991;115:223-34.
95. Hammerschmidt DE, Kotasek D, McCarthy T, Huh PW, Freyburger G, Vercellotti GM. Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor. J Lab Clin Med 1988;112:254-63.
96. Hanazawa S, Prewitt RL, Terzis JK. The effect of pentoxifylline on ischemia and reperfusion injury in the rat cremaster muscle. J Reconstr Microsurg 1994;10:21-6.
97. Bahrami S, Yao YM, Shiga H, Leichtfried G, Redl H, Schlag G. Comparison of the efficacy of pentoxifylline and albifyllin (HWA 138) on endotoxin-induced cytokine production, coagulation disturbances, and mortality. Shock 1996;5:424-8.
98. Chapelier A, Reignier J, Mazmanian M, et al. Pentoxifylline and lung ischemia-reperfusion injury: Application to lung transplantation. Universite Paris-Sud Lung Transplant Group. J Cardiovasc Pharmacol 1995;25(Suppt 2):S130-3.
99. Savas C, Aras T, Cakmak M, et al. Pentoxifylline inhibits overflow and reduces intestinal reperfusion injury. J Pediatr Surg 1997;32:905-10.
100. Savas C, Dindar H, Aras T, Yucesan S. Pentoxifylline improves blood flow to both testes in testicular torsion. Int Urol Nephrol 2002;33:81-5.
101. Savas C, Dindar H, Bilgehan A, Ataoglu O, Yucesan S. Pentoxifylline attenuates reperfusion injury in testicular torsion. Scand J Urol Nephrol 2002;36:65-70.
102. Creager MA. Medical management of peripheral arterial disease. Cardiol Rev 2001;9:238-45.
103. Capron L. Pharmacologic approaches to the treatment of atherosclerotic arterial obstruction. J Cardiovasc Pharmacol 1995;25(Suppl 2):S40-3.
104. Dormandy JA, Hoare E, Colley J, Arrowsmith DE, Dormandy TL. Clinical, haemodynamic, rheological, and biochemical findings in 126 patients with intermittent claudication. Br Med J 1973;4:576-81.
105. Ott E, Lechner H, Fazekas F. Hemorheological effects of pentoxifylline on disturbed flow behavior of blood in patients with cerebrovascular insufficiency. Eur Neurol 1983;22(Suppl 1):105-7.
106. Chen YM, Wu KD, Tsai TJ, Hsieh BS. Pentoxifylline inhibits PDGF-induced proliferation of and TGF-beta-stimulated collagen synthesis by vascular smooth muscle cells. J Mol Cell Cardiol 1999;31:773-83.
107. Dosquet C, Weill D, Wautier JL. Cytokines and thrombosis. J Cardiovasc Pharmacol 1995;25(Suppl 2):S13-9.
108. Wakefield PE, James WD, Samlaska CP, Meltzer MS. Tumor necrosis factor. J Am Acad Dermatol 1991;24:675-85.
109. McNamara DB, Champion HC, Kadowitz PJ. Pharmacologic management of peripheral vascular disease. Surg Clin North Am 1998;78:447-64.
110. Muller R. Pentoxifylline - a biomedical profile. J Med 1979;10:307-29.
111. Strano A, Davi G, Avellone G, Novo S, Pinto A. Double-blind, crossover study of the clinical efficacy and the hemorheological effects of pentoxifylline in patients with occlusive arterial disease of the lower limbs. Angiology 1984;35:459-66.
112. Wu CC, Liao MH, Chen SJ, Yen MH. Pentoxifylline improves circulatory failure and survival in murine models of endotoxaemia. Eur J Pharmacol 1999;373:41-9.
113. Haustein KO. State of the art - treatment of peripheral occlusive arterial disease (POAD) with drugs vs. vascular reconstruction or amputation. Int J Clin Pharmacol Ther 1997;35:266-74.
114. Dinn RF, Yang HT, Terjung RL. The influence of pentoxifylline and torbafylline on muscle blood flow in animals with peripheral arterial insufficiency. J Clin Pharmacol 1990;30:704-10.
115. Hoeffner U, Aarhus LL, Katusic ZS, Vanhoutte PM. Pharmacology of pentoxifylline in isolated canine arteries and veins. J Cardiovasc Pharmacol 1989;14:899-907.
116. Hudlicka O, Price S. Effects of torbafylline, pentoxifylline and buflomedil on vascularisation and fibre type of rat skeletal muscles subjected to limited blood supply. Br J Pharmacol 1990;99:786-90.
117. Kamphuis J, Smits P, Thien T. Vascular effects of pentoxifylline in humans. J Cardiovasc Pharmacol 1994;24:648-54.
118. Seiffge D. Pentoxifylline: its influence on the interaction of blood cells with the vessel wall. Atherosclerosis 1997;131(Suppl):S27-8.
119. Blayney L, Thomas H, Muir J, Henderson A. Action of caffeine on calcium transport by isolated fractions of myofibrils, mitochondria, and sarcoplasmic reticulum from rabbit heart. Circ Res 1978;43:520-6.
120. Fredholm BB, Lindstrom K. The xanthine derivative 1-(5′-oxohexyl)-3-methyl-7-propyl xanthine (HWA 285) enhances the actions of adenosine. Acta Pharmacol Toxicol (Copenh) 1986;58:187-92.
121. Wu PH, Barraco RA, Phillis JW. Further studies on the inhibition of adenosine uptake into rat brain synaptosomes by adenosine derivatives and methylxanthines. Gen Pharmacol 1984;15:251-4.
122. Belch JJ, Ho M. Pharmacotherapy of Raynaud's phenomenon. Drugs 1996;52:682-95.
123. Chopra HK, Chopra KL, Aggarwal KK, Parashar SK. Pentoxifylline (Trental) - a new drug for the treatment of peripheral chronic occlusive arterial disease. J Med 1988;19:89-107.
124. Chirkov YY, Chirkova LP, Sage RE, Horowitz JD. Impaired responsiveness of platelets from patients with stable angina pectoris to antiaggregating and cyclic AMP-elevating effects of prostaglandin E1. J Cardiovasc Pharmacol 1995;25:961-6.
125. Muller R, Lebrach F. Haemorheological role of platelet aggregation and hypercoagulability in microcirculation: Therapeutical approach with pentoxifylline. Pharmatherapeutica 1980;2:372-9.
126. Berry CN, Lorrain J, Lochot S, et al. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist. Thromb Haemost 2001;85:521-8.
127. Becker RC. The role of blood viscosity in the development and progression of coronary artery disease. Cleve Clin J Med 1993;60:353-8.
128. Beyreder J. Use of pentoxifylline in the treatment of acute cerebrovascular insufficiency. Eur Neurol 1983;22(Suppl 1):116-23.
129. Dintenfass L. The clinical impact of the newer research in blood rheology: An overview. Angiology 1981;32:217-29.
130. Kwaan HC, Bongu A. The hyperviscosity syndromes. Semin Thromb Hemost 1999;25:199-208.
131. Lechner H, Ott E, Bertha G. Therapeutical aspects of cerebrovascular disease. Eur Neurol 1983;22(Suppl 1):74-7.
132. Levenson J, Del Pino M, Simon A. [Blood and arterial wall rheology and cardiovascular risk factors.] J Mal Vasc 2000;25:237-40.
133. Nash GB. Blood rheology and ischaemia. Eye 1991;5:151-8.
134. Liu M, Counsell C, Wardlaw J. Fibrinogen depleting agents for acute ischaemic stroke. Cochrane Database Syst Rev 2000;CD000091.
135. Ehrly AM. Drugs that alter blood viscosity. Their role in therapy. Drugs 1990;39:155-9.
136. Ely H. Pentoxifylline therapy in dermatology. A review of localized hyperviscosity and its effects on the skin. Dermatol Clin 1988;6:585-608.
137. Bath PM, Bath FJ, Asplund K. Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke. Cochrane Database Syst Rev 2000;CD000162.
138. Ernst E. Pentoxifylline for intermittent claudication. A critical review. Angiology 1994;45:339-45.
139. Schneider R, Schmid-Schonbein H, Kiesewetter H. The rheological efficiency of parenteral pentoxifylline (Trental) in patients with ischemic brain lesions. Preliminary results. Eur Neurol 1983;22(Suppl 1):98-104.
140. Mukherjee D, Topol EJ. The role of low-molecular-weight heparin in cardiovascular diseases. Prog Cardiovasc Dis 2002;45:139-56.
141. Nowak SN, Jaber LA. Aspirin dose for prevention of cardiovascular disease in diabetics. Ann Pharmacother 2003;37:116-21.
142. Sawczuk IS, Williams D, Chang DT. Low molecular weight heparin for venous thromboembolism prophylaxis in urologic oncologic surgery. Cancer Invest 2002;20:889-92.
143. Windmeier C, Gressner AM. Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis. Gen Pharmacol 1997;29:181-96.
144. Isbrucker RA, Peterson TC. Platelet-derived growth factor and pentoxifylline modulation of collagen synthesis in myofibroblasts. Toxicol Appl Pharmacol 1998;149:120-6.